PCFTF News Alert Pacific Therapeutics (PCFTF) 0.0344 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pacific Therapeutics (PCFTF) 0.0344 $PCFTF

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 325.13 (-10.67), GILD: 100.46 (-2.70), CGEN: 7.98 (-0.01), ASPX: 25.09 (+0.78), GSK: 41.92 (+0.62), BMY: 57.69 (-0.86)

Pacific Therapeutics Announces First Nine Months 2014 Financial Results
ACCESSWIRE - Tue Dec 02, 3:54PM CST
VANCOUVER, BC / ACCESSWIRE / December 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (1P3.F) (the "Company" has completed a phase 1 trial of its lead product for fibrosis, PTL-202, (a $4 billion market opportunity) with positive results and is advancing its sublingual formulation for erectile dysfunction (ED) to a pivotal bioequivalence trial.

CEO Comments on Diagnostic Breakthrough for Pulmonary Fibrosis
ACCESSWIRE - Thu Nov 13, 7:35AM CST
VANCOUVER, BC, Canada / ACCESSWIRE / November 13, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $4 billion plus market opportunities.

Pacific Therapeutics CEO Comments on Big Pharmas Recent Interest In Acquiring Therapies to treat Fibrosis
ACCESSWIRE - Thu Nov 06, 7:32AM CST
VANCOUVER, BC, Canada / ACCESSWIRE / November 6, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $4 billion plus market opportunities.

Pacific Therapeutics Ltd. Issues Stock Options to Consultants
TheNewswire.ca - Wed Nov 05, 9:05AM CST
(via Thenewswire.ca)

Pacific Therapeutics Shares Article Explaining Rose Mcgowan's Kiss IPF Goodbye Campaign
ACCESSWIRE - Thu Oct 09, 7:31AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / October 9, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Pacific Therapeutics Annonuces Closing Of Non-Brokered Financing
ACCESSWIRE - Thu Oct 02, 7:40AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / October 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

Pacific Therapeutics Announces Amendment to Non-Brokered Financing
ACCESSWIRE - Tue Sep 23, 7:31AM CDT
VANCOUVER, BC / ACCESSWIRE / September 23, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Pacific Therapeutics Shares Vancouver Sun Article Explaining Positive Impact of Cannabis on Child Having Epileptic Seizures and Need for New Formulations
ACCESSWIRE - Tue Sep 16, 7:06AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 16, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Update on PTL-202, a Treatment for Progressive Organ Scarring, a $1.1 Billion Opportunity
ACCESSWIRE - Thu Sep 04, 7:39AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 4, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.
ITMN: 73.89 (-0.02)

Vantage Wire Publishes Report on Pacific Therapeutics Partner Vodis Innovative Pharmaceuticals
ACCESSWIRE - Tue Sep 02, 3:32PM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Pacific Therapeutics Announces First Six Months 2014 Financial Results
ACCESSWIRE - Thu Aug 28, 5:13PM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 28, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTCBB: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on erectile dysfunction and diseases of excessive scarring (fibrosis) which are $1 billion plus market opportunities.

H.C. Wainwright Initiates Coverage of Pacific Therapeutics Partner Intelgenx with a Buy Recommendation
ACCESSWIRE - Fri Aug 15, 7:48AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 15, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Vodis Pharmaceuticals and Pacific Therapeutics Agree to Share Technologies to Deliver Cannabinoid Based Therapies
ACCESSWIRE - Tue Aug 05, 8:08AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 5, 2014 / Vodis Pharmaceuticals (CSE: VP) (the "Company" The Company is pleased to announce that it has signed a term sheet with Pacific Therapeutics ("Pacific" agreeing to work with Pacific on the development of therapies based on extracts from cannabis plants, as previously announced by Pacific Therapeutics (PT:cse).

Pacific Therapeutics Annonuces Non-Brokered Financing
ACCESSWIRE - Tue Aug 05, 7:33AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 5, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Proactive Investor Publishes Article on Pacific Therapeutics
ACCESSWIRE - Fri Jul 25, 7:32AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 25, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 22

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 92

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 26

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 11

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 57

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 239

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Charlotte's Web Moves Forward with AJA001 Autism Treatment Trial

Updated Category News Views 280

Charlotte's Web Progresses to Phase 2 in Autism Treatment Charlotte's Web Holdings, Inc. (TSX: CWEB) has announced an important step in the development of its botanical drug known as AJA001, aimed at treating symptoms associated with autism spectrum disorder (ASD). The U.S. Food and Drug Administration (FDA) has officially issued a green light for Charlotte's Web and its...

Continue Reading
Uptown Cheapskate and Kid to Kid Celebrate Monumental Growth

Updated Category News Views 257

Uptown Cheapskate and Kid to Kid Celebrate Monumental Growth Uptown Cheapskate and Kid to Kid have reached an amazing milestone, surpassing $300 million in system-wide sales during a recent year, showcasing a remarkable growth of over 20% compared to the previous year. This achievement is a testament to the increasing consumer demand for thrift shopping and the unique...

Continue Reading
Exploring the Thriving Landscape of Smart Wearables Market Trends

Updated Category News Views 146

Overview of the Smart Wearables Market Growth The Smart Wearables market is on an exciting upward trajectory, expected to surge from its valuation of USD 77.95 billion to an impressive USD 319.42 billion by 2032. With a robust compound annual growth rate (CAGR) of 19.34%, the sector reflects significant consumer interest and technological advancements. This remarkable...

Continue Reading
Exciting Partnership: Bass Pro Shops and the SMX League Unite

Updated Category News Views 239

Bass Pro Shops Teams Up With The SMX League Bass Pro Shops is set to become the official partner across the entire SMX racing calendar. One of the most thrilling events to look forward to is the Monster Energy SMX World Championship Final, which is scheduled to take place at Thunder Ridge, creating an exciting experience for fans. Venue Selection for The Championship...

Continue Reading
ADI Foundation Launches Innovative ADI Chain Mainnet and Token

Updated Category News Views 172

Exciting Developments from the ADI Foundation The ADI Foundation has recently launched the mainnet of ADI Chain along with its native ADI utility token. This significant step establishes a specialized Layer-2 blockchain aimed at enhancing operations for governments, regulated entities, and various real-world applications. By creating a tailored blockchain environment, the...

Continue Reading